IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
IQVIA HOLDINGS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$265.88−1.02 (-0.38%)
Close on Oct 19, 2026
- Market cap
- $44.48B
- P/E (TTM)
- 33.0
- Dividend yield
- –
IQVIA HOLDINGS INC. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Solutions | $2.58B | $2.40B | $2.33B | $2.26B | $2.37B | $2.26B | $2.12B | $2.16B | $2.15B | $2.10B | $2.15B | $2.12B | 59.0% | +8.8% |
| Commercial Solutions | $1.79B | $1.75B | – | – | $1.65B | $1.57B | – | – | – | – | – | – | 41.0% | +8.6% |
| Technology And Analytics Solutions | – | – | $1.82B | $1.63B | $1.63B | $1.55B | $1.66B | $1.55B | $1.50B | $1.45B | $1.53B | $1.43B | – | – |
| Contract Sales & Medical Solutions | – | – | $210.00M | $209.00M | $188.00M | $181.00M | $177.00M | $180.00M | $172.00M | $189.00M | $186.00M | $183.00M | – | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $2.04B | $1.98B | $2.07B | $1.93B | $1.94B | $1.81B | $1.85B | $1.84B | $1.86B | $1.80B | $2.07B | $1.86B | 46.7% | +5.4% |
| Europe and Africa | $1.41B | $1.36B | $1.42B | $1.30B | $1.24B | $1.22B | $1.30B | $1.29B | $1.18B | $1.16B | $1.16B | $1.09B | 32.3% | +13.5% |
| Asia-Pacific | $920.00M | $812.00M | $871.00M | $870.00M | $841.00M | $798.00M | $807.00M | $771.00M | $773.00M | $778.00M | $634.00M | $791.00M | 21.1% | +9.4% |
From the segment and revenue-disaggregation notes of Iqvia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.